Vinod H. Thourani, MD on behalf of The PARTNER Trial Investigators
Craig R. Smith, MD on behalf of The PARTNER Trial Investigators
-
Upload
joseph-carroll -
Category
Documents
-
view
27 -
download
3
description
Transcript of Craig R. Smith, MD on behalf of The PARTNER Trial Investigators
![Page 1: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/1.jpg)
Craig R. Smith, MDon behalf of The PARTNER Trial Investigators
Transcatheter vs. Surgical Aortic Valve Replacement in High Risk Patients with Severe Aortic Stenosis: Results From The PARTNER Trial
ACC 2011 | New Orleans | April 3, 2011
![Page 2: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/2.jpg)
Craig R. Smith, MD
PARTNER Trial sponsor (Edwards LifeSciences) reimburses customary travel and other expenses
Presenter Disclosure Information Presenter Disclosure Information for PARTNER at ACC April 3, 2011for PARTNER at ACC April 3, 2011
![Page 3: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/3.jpg)
BackgroundBackground
• Surgical aortic valve replacement (AVR) is the standard of care for treating patients with symptomatic aortic stenosis who are candidates for operation.
• Although transcatheter aortic valve replacement (TAVR) reduces mortality in patients who cannot have AVR, there have been no randomized trials comparing TAVR to AVR in patients who are at high-risk for operation.
![Page 4: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/4.jpg)
PurposePurpose
To compare the safety and effectiveness of TAVR (either transfemoral or transapical) to surgical AVR in high-risk, operable patients with symptomatic, severe aortic stenosis.
![Page 5: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/5.jpg)
N = 699 N = 358High RiskHigh Risk InoperableInoperable
PARTNER Study DesignPARTNER Study Design
Symptomatic Severe Aortic StenosisSymptomatic Severe Aortic Stenosis
ASSESSMENT: High-Risk AVR Candidate3,105 Total Patients Screened
ASSESSMENT: High-Risk AVR Candidate3,105 Total Patients Screened
Total = 1,057 patients
2 Parallel Trials: Individually Powered
StandardTherapyStandardTherapy
ASSESSMENT: Transfemoral
Access
ASSESSMENT: Transfemoral
Access
Not In StudyNot In Study
TF TAVRTF TAVR
Primary Endpoint: All-Cause Mortality Over Length of Trial (Superiority)
Co-Primary Endpoint: Composite of All-Cause Mortalityand Repeat Hospitalization (Superiority)
Primary Endpoint: All-Cause Mortality Over Length of Trial (Superiority)
Co-Primary Endpoint: Composite of All-Cause Mortalityand Repeat Hospitalization (Superiority)
1:1 Randomization1:1 Randomization
VS
YesYes NoNo
N = 179 N = 179
![Page 6: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/6.jpg)
Inoperable PARTNER CohortInoperable PARTNER CohortPrimary Endpoint: Primary Endpoint: All-Cause MortalityAll-Cause Mortality
Numbers at RiskNumbers at Risk
TAVITAVI 179179 138138 122122 6767 2626 Standard RxStandard Rx 179179 121121 8383 4141 1212
Standard Rx
TAVI
All-
caus
e m
orta
lity
(%)
Months
∆ at 1 yr = 20.0%NNT = 5.0 pts 50.7%
30.7%
HR [95% CI] =0.54 [0.38, 0.78]
P (log rank) < 0.0001
Leon et al, NEJM 2010; 363:1597-1607
![Page 7: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/7.jpg)
N = 179
N = 358InoperableInoperable
StandardTherapyStandardTherapy
ASSESSMENT: Transfemoral
Access
ASSESSMENT: Transfemoral
Access
Not In StudyNot In Study
TF TAVRTF TAVR
Primary Endpoint: All-Cause Mortality Over Length of Trial (Superiority)
Co-Primary Endpoint: Composite of All-Cause Mortalityand Repeat Hospitalization (Superiority)
Primary Endpoint: All-Cause Mortality Over Length of Trial (Superiority)
Co-Primary Endpoint: Composite of All-Cause Mortalityand Repeat Hospitalization (Superiority)
1:1 Randomization1:1 Randomization
VS
YesYes NoNo
N = 179
TF TAVRTF TAVR AVRAVR
Primary Endpoint: All-Cause Mortality at 1 yr(Non-inferiority)
Primary Endpoint: All-Cause Mortality at 1 yr(Non-inferiority)
TA TAVRTA TAVR AVRAVR VS
VS
N = 248 N = 104 N = 103N = 244
PARTNER Study DesignPARTNER Study Design
Symptomatic Severe Aortic StenosisSymptomatic Severe Aortic Stenosis
ASSESSMENT: High-Risk AVR Candidate3,105 Total Patients Screened
ASSESSMENT: High-Risk AVR Candidate3,105 Total Patients Screened
Total = 1,057 patients
2 Parallel Trials: Individually Powered
N = 699 High RiskHigh Risk
ASSESSMENT: Transfemoral
Access
ASSESSMENT: Transfemoral
Access
Transapical (TA)Transapical (TA)Transfemoral (TF)Transfemoral (TF)
1:1 Randomization1:1 Randomization1:1 Randomization1:1 Randomization
YesYes NoNo
![Page 8: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/8.jpg)
Primary EndpointPrimary Endpoint
All-cause mortality at one yearAll-cause mortality at one year
•Analysis by intent-to-treat
•Event rates by Kaplan-Meier estimates•Crossovers permitted only when assignedtherapy unsuccessful
•All patients followed for ≥ one year
![Page 9: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/9.jpg)
Other Important Endpoints (1)Other Important Endpoints (1)
Safety:Safety:• Neurologic events
– Prospective: Stroke and stroke plus TIA (all neuro events)
– Retrospective: Major stroke (modified Rankin Score ≥ 2 @ ≥ 30 days)
• Major vascular complications (VARC definition)
• Major bleeding (modified VARC definition)
• Repeat hospitalization
• New pacemakers and new-onset atrial fibrillation (ECG core lab)
• Procedural events (assigned therapy aborted or converted to AVR, multiple valves, etc.)
• Surgical complications (re-op for bleeding, sternal infection, etc.)
![Page 10: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/10.jpg)
Other Important Endpoints (2)Other Important Endpoints (2)
Clinical Effectiveness and Valve Performance:Clinical Effectiveness and Valve Performance:
• NYHA symptoms
• Six-minute walk tests
• Quality-of-life measures and cost-effectiveness (core lab)
• Echocardiography assessment of valve performance (core lab)
– Peak and mean gradients– Effective orifice area– Bioprosthetic valve regurgitation (esp. para-valvular)– Other: LV ejection fraction, MR, LV mass, evidence of structural
valve deterioration
![Page 11: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/11.jpg)
Co-Principal Investigators
Martin B. Leon, Craig R. SmithColumbia University Medical Center
Executive Committee
Martin B. Leon, Michael Mack, D. Craig Miller, Jeffrey W. Moses,Craig R. Smith, Lars G. Svensson, E. Murat Tuzcu, John G. Webb
Data & Safety Monitoring Board
Chairman: Joseph P. CarrozzaTufts University School of Medicine
Clinical Events Committee
Chairman: John L. PetersenDuke University Medical Center
Echo Core Laboratory
Chairman: Pamela C. Douglas Duke University Medical Center
Quality of Life and Cost-Effectiveness
Chairman: David J. CohenMid America Heart Institute, Kansas City
Independent BiostatisticalCore Laboratory
Stuart Pocock, Duolao WangLondon School of Hygiene andTropical Medicine
William N. Anderson
Publications Committee
Co-Chairman: Jeffrey W. MosesLars G. Svensson
Sponsor
Edwards Lifesciences: Jodi J. Akin
Study AdministrationStudy Administration
![Page 12: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/12.jpg)
Executive Committee Executive Committee
John Webb
Murat Tuzcu
Marty Leon
Jeff MosesLars Svensson Craig Miller Michael Mack
Craig Smith
![Page 13: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/13.jpg)
Participating Study SitesParticipating Study Sites
Intermountain Medical CenterSalt Lake City, UT
Emory UniversityAtlanta, GA
Univ. of MiamiMiami, FL
Univ. of Virginia Charlottesville, VA
St. Luke’s Hospital Kansas City, MO
Barnes-Jewish HospitalSt. Louis, MO
Medical City DallasDallas, TX
St. Paul's HospitalVancouver, Canada
Univ. of WashingtonSeattle, WA
Mayo ClinicRochester, MN
Stanford UniversityPalo Alto, CA
Hospital LavalQuebec City,
Canada
Ochsner FoundationNew Orleans, LA
Scripps ClinicLa Jolla, CA
Cedars-Sinai Medical CenterLos Angeles, CA
Cleveland ClinicCleveland, OH
Columbia UniversityCornell University New York, NY
Washington Hosp. CenterWash., DC
Univ. of Penn Phila., PA
Brigham & Women’sMass GeneralBoston, MA
Northwestern Univ.Chicago, IL
Toronto Gen. Hospital
Toronto, Canada
Evanston Hospital
Leipzig Heart Center Leipzig, Germany
n = 1,057 patients26 investigator sites22 USA, 3 Canada, 1 Germany
![Page 14: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/14.jpg)
High-Risk Enrollment by SiteHigh-Risk Enrollment by Site
Cedars-Sinai Medical CtrLos Angeles, CAG. Fontana, R. Makkar
116
Columbia University New York City, NYM. Leon, C. Smith
97
Medical City DallasDallas, TXD. Brown, T. Dewey
95
Emory UniversityAtlanta, GAP. Block, R. Guyton
67
University of PennsylvaniaPhiladelphia, PAJ. Bavaria, H. Herrmann
52
Cleveland Clinic FoundCleveland, OHL. Svensson, M. Tuzcu
47
Washington Hospital CtrDistrict of ColumbiaP. Corso, A. Pichard
40
University of MiamiMiami, FLW. O’Neill, D. Williams
25
Barnes-Jewish HospitalSt. Louis, MOR. Damiano, J, Lasala
24
Stanford UniversityPalo Alto, CAC. Miller, A. Yeung
23
Northwestern UniversityChicago, ILC. Davidson, P. McCarthy
20
St. Paul's HospitalVancouver, BC, CanadaA. Cheung, J. Webb
19
![Page 15: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/15.jpg)
Mass General Hospital Boston, MAI. Palacios, G. Vlahakis
15
St. Luke’s HospitalKansas City, MOK. Allen, D. Cohen
13
Universitaire de QuebecLaval, Quebec, CAD. Doyle, J. Rodes-Cabau
8
Scripps Clinic La Jolla, CAS. Brewster, P. Teirstein
7
Herzzentrum LeipzigLeipzig, GermanyF. Mohr, G. Schuler
7
Mayo ClinicRochester, MNC. Rihal, T. Sundt
6
Univ of WashingtonSeattle, WAM. Reisman, E. Verrier
5
Northshore Univ Health SysEvanston, ILJ. Alexander, T. Feldman
4
University of Virginia Charlottesville, VAI. Kron, S. Lim
3
Brigham & Women’s HospBoston, MAM. Davidson, A. Eisenhauer
2
Ochsner FoundationNew Orleans, LAE. Parrino, S. Ramee
2
Intermountain Med CenterSalt Lake City, UTK. Jones, B. Whisenant
1
Cornell University New York City, NYK. Krieger, C. Wong
1
Toronto General HospitalToronto, Ontario, CAC. Feindel, E. Horlick
0
High-Risk Enrollment by SiteHigh-Risk Enrollment by Site
![Page 16: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/16.jpg)
Study DevicesStudy Devices
Edwards SAPIEN THV23 and 26 mm valves
RetroFlex 22 and 24 F sheaths
Ascendra 24 and 26 F sheaths
![Page 17: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/17.jpg)
TransfemoralTransfemoral TransapicalTransapical
TAVRTAVRTransfemoral and TransapicalTransfemoral and Transapical
![Page 18: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/18.jpg)
Inclusion CriteriaInclusion Criteria
• Severe AS: Echo-derived AVA < 0.8 cm2 (or AVA index < 0.5 cm2/m2) and mean AVG > 40 mm Hg or peak jet velocity > 4.0 m/s
• Cardiac Symptoms: NYHA Functional Class ≥ II
• High surgical risk: Predicted risk of operative mortality ≥ 15% (determined by site surgeon and cardiologist); guideline = STS score ≥ 10
![Page 19: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/19.jpg)
Key Exclusion Criteria (1)Key Exclusion Criteria (1)
• Bicuspid or non-calcified aortic valve
• Aortic annulus diameter (echo measurement) < 18 mm or > 25 mm
• Aortic dissection or iliac-femoral dimensions or diseaseprecluding safe sheath insertion (esp. calcification)
• Severe LV dysfunction (LVEF < 20%)
• Untreated CAD requiring revascularization
• Severe AR or MR (> 3+) or prosthetic valve (any location)
Anatomic:Anatomic:
![Page 20: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/20.jpg)
Key Exclusion Criteria (2)Key Exclusion Criteria (2)
• Serum Cr > 3.0 mg/dL or dialysis dependent
• Acute MI within 1 monthAcute MI within 1 month
• Upper GI bleed within 3 monthsUpper GI bleed within 3 months
• CVA or TIA within 6 monthsCVA or TIA within 6 months
• Any cardiac procedure, other than BAV, within 1 month Any cardiac procedure, other than BAV, within 1 month or within 6 months for DESor within 6 months for DES
• Hemodynamic instability (e.g. requiring inotropic support)Hemodynamic instability (e.g. requiring inotropic support)
Clinical:Clinical:
![Page 21: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/21.jpg)
Statistical Analysis PlanStatistical Analysis Plan
• Primary hypothesis is non-inferiority of test (TAVR)vs. control (AVR) for all-cause mortality at 1 year
• Non-inferior if one-sided 95% upper confidence limit forthe treatment difference is < 7.5% (α =0.05)
• Primary Endpoint: All TF and TA patients– Assuming true 1-year mortality 32% after AVR and 29% after TAVR– Intended sample size = 650 patients for ≥ 85% power
• Powered Secondary Endpoint: Only TF patients– Assuming true 1-year mortality 35% after AVR and 25% after TAVR– Intended sample size = 450 patients for ≥ 85% power
![Page 22: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/22.jpg)
Study Methodology Study Methodology
• Preliminary eligibility determined by site investigators
• Every case reviewed by web-based conference callbefore enrollment
• Randomized to TF-TAVR vs. AVR, or TA-TAVR vs. AVR, to be treated within 2 weeks
• Intent-to-treat (ITT) analysis for the primary and most secondary endpoints; defined as the time of randomization
• As-treated (AT) analysis for some procedural endpointsand for echo assessments; defined as thetime of procedural anesthesia induction
![Page 23: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/23.jpg)
1 Year (189)Dead = 46Withdrawal = 1
1 Year (189)Dead = 46Withdrawal = 1
1 Year (168)Dead = 47Withdrawal = 8
1 Year (168)Dead = 47Withdrawal = 8
Study FlowStudy Flow
AVR (248)AVR (248)
30 Days (236)Dead = 8Withdrawal = 0
30 Days (236)Dead = 8Withdrawal = 0
Randomized = 699 patients
TF = 492TA = 207
Transfemoraln = 492
Transfemoraln = 492
TAVR (244)TAVR (244)
30 Days (223)Dead = 15Withdrawal = 10
30 Days (223)Dead = 15Withdrawal = 10
1 Year (73)Dead = 26Withdrawal = 0LTFU = 1
1 Year (73)Dead = 26Withdrawal = 0LTFU = 1
1 Year (68)Dead = 20Withdrawal = 3LTFU = 1
1 Year (68)Dead = 20Withdrawal = 3LTFU = 1
AVR (103)AVR (103)
30 Days (100)Dead = 4Withdrawal = 0
30 Days (100)Dead = 4Withdrawal = 0
Transapicaln = 207
Transapicaln = 207
TAVR (104)TAVR (104)
30 Days (92)Dead = 7Withdrawal = 4
30 Days (92)Dead = 7Withdrawal = 4
42 Patients not treated as assigned
![Page 24: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/24.jpg)
ReasonReason TAVR (N = 348)TAVR (N = 348) AVR (N = 351)AVR (N = 351)
Died before treatment - no. (%) 2 (0.6) 5 (1.4)
Deterioration before treatment - no. (%) 1 (0.3) 5 (1.4)
Refusal - no. (%) 1 (0.3) 17 (4.8)
Withdrawal - no. (%) 0 11 (3.1)
Total – no. (%)Total – no. (%) 4 (1.1)4 (1.1) 38 (10.8)38 (10.8)
Reasons for Non-treatmentReasons for Non-treatment
ITT = 699 patients │ AT = 657 patients
NOTE: Time from randomization to treatment = TAVR 10.6 [SEM 0.7] daysvs. AVR 15.6 [SEM 1.1] days; P <0.001
![Page 25: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/25.jpg)
CharacteristicCharacteristic TAVR (N = 348)TAVR (N = 348) AVR (N = 351)AVR (N = 351) p-valuep-value
Age (yr) 83.6 ± 6.8 84.5 ± 6.4 0.07
Male sex - % 57.8 56.7 0.82
STS Score 11.8 ± 3.3 11.7 ± 3.5 0.61
Logistic EuroSCORE 29.3 ± 16.5 29.2 ± 15.6 0.93
NYHAII - %
III or IV - % 94.3 94.0 0.79
CAD - % 74.9 76.9 0.59
Previous MI - % 26.8 30.0 0.40
Prior CV Intervention - % 72.1 71.6 0.93
Prior CABG - % 42.6 44.2 0.70
Prior PCI - % 34.0 32.5 0.68
Prior BAV - % 13.4 10.2 0.24
29.3 27.4 0.60
Patient Characteristics (1) Patient Characteristics (1)
Cerebrovascular disease - %
5.7 6.0
![Page 26: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/26.jpg)
CharacteristicCharacteristic TAVR (N = 348)TAVR (N = 348) AVR (N = 351)AVR (N = 351) p-valuep-value
Peripheral vascular disease - % 43.0 41.6 0.76
COPD Any 43.4
Oxygen dependent 9.2 7.1 0.34
Creatinine > 2mg/dL - % 11.1 7.0 0.06
Atrial fibrillation - % 40.8 42.7 0.75
Permanent pacemaker - % 20.0 21.9 0.58
Pulmonary hypertension - % 42.4 36.4 0.15
Frailty - % 15.6 17.6 0.58
Porcelain aorta - % 0.6 1.1 0.69
Chest wall radiation - % 0.9 0.9 1.00
Liver disease - % 2.0 2.6 0.80
Patient Characteristics (2) Patient Characteristics (2)
43.0 0.94
![Page 27: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/27.jpg)
Baseline Echocardiography Baseline Echocardiography
Echo FindingsEcho Findings TAVR (N = 348)TAVR (N = 348) AVR (N = 351)AVR (N = 351) p-valuep-value
AVA - cm2 0.7 ± 0.2 0.6 ± 0.2 0.13
AVG - mm Hg 42.7 ± 14.6 43.5 ± 14.3 0.45
Mean LVEF - % 52.5 ± 13.5 53.3 ± 12.8 0.45
Moderate or severe MR - % 19.8 21.3 0.63
![Page 28: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/28.jpg)
Anesthesia time - min 330
Total procedure time - min 230
Aborted procedure - no. (%) 0
Reoperation for bleeding - no. (%) 12 (3.4)
Intra-procedural death - no. (%) 1 (0.3)
Aortic perforation - no. (%) 1 (0.3)
Aortic dissection - no. (%) 3 (0.9)
Median ICU stay (days) 5.0
Anesthesia time - min 236
Total procedure time - min 133
Aborted procedure - no. (%) 7 (2.0)
Reoperation for bleeding - no. (%) 2 (0.6)
Intra-procedural death - no. (%) 3 (0.9)
Aortic perforation - no. (%) 0
Aortic dissection - no. (%) 3 (0.9)
Median ICU stay (days) 3.0
Procedural Outcomes - TAVR vs AVRProcedural Outcomes - TAVR vs AVR
*Converted to transapical TAVR due to porcelain aorta
AVR TAVR
3 failed access2 new TEE findings
2 died
3 failed access2 new TEE findings
2 diedAborted procedure - no. (%)Aborted procedure - no. (%)
![Page 29: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/29.jpg)
Sternal wound infection - no. (%) 7 (2.0)
Total cross clamp time - min 74
Pump time - min 105
Access site infection - no. (%) 7 (2.0)
Fluoroscopy time - min 31
Converted to AVR - no. (%) 9 (2.6)
Multiple (≥2) valves - no. (%) 7 (2.0)
Valve embolization - no. (%) 9 (2.6)
Procedural Outcomes - TAVR vs AVRProcedural Outcomes - TAVR vs AVR
*Converted to transapical TAVR due to porcelain aorta
AVR TAVR
5 valve embolization3 annulus size on TEE
1 large sigmoid septum
5 valve embolization3 annulus size on TEE
1 large sigmoid septumConverted to AVR - no. (%)Converted to AVR - no. (%)
5 converted to AVR2 valve-in-valve
2 not treated
5 converted to AVR2 valve-in-valve
2 not treatedValve embolization - no. (%)Valve embolization - no. (%)
![Page 30: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/30.jpg)
0
0.1
0.2
0.3
0.4
0.5
0 6 12 18 24
TAVR
AVR
Months
348 298 260 147 67
351 252 236 139 65
No. at Risk
TAVR
AVR
26.8
24.2
Primary Endpoint:Primary Endpoint:All-Cause Mortality at 1 YearAll-Cause Mortality at 1 Year
HR [95% CI] =0.93 [0.71, 1.22]
P (log rank) = 0.62
![Page 31: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/31.jpg)
Primary Endpoint:Primary Endpoint:All-Cause Mortality at 1 YearAll-Cause Mortality at 1 Year
7.0-2.0 -1.0 0.0 6.03.0 4.0 5.0-3.0 1.0 2.0
Non-inferior
Upper one-sided 95% CI
8.0 %
AVR (N = 351)
26.8%
AVR (N = 351)
26.8%
TAVR (N = 348)
24.2%
TAVR (N = 348)
24.2%
Difference -2.6%
Upper 1-sided Upper 1-sided 95% CI95% CI3.0%3.0%
Difference -2.6%
Upper 1-sided Upper 1-sided 95% CI95% CI3.0%3.0%
Primary Non-Inferiority Endpoint MetPrimary Non-Inferiority Endpoint Met
Non-inferiority
P value
= 0.001
Non-inferiority
P value
= 0.001
Zone of non-inferiority pre-specified margin = 7.5%
![Page 32: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/32.jpg)
All-Cause MortalityAll-Cause MortalityTransfemoral (N=492)Transfemoral (N=492)
Months
244 215 188 119 59
248 180 168 109 56
No. at Risk
TAVR
AVR
26.4
22.2
HR [95% CI] =0.83 [0.60, 1.15]
P (log rank) = 0.25
![Page 33: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/33.jpg)
Powered Secondary Endpoint (ITT):TF All-Cause Mortality at 1 Year
7.0-4.0 -1.0 0.0 6.03.0 4.0 5.0-5.0
Zone of non-inferiority pre-specified margin = 7.5%
1.0 2.0
Non-inferior
Upper one-sided 95% CI
Secondary TF Non-Inferiority Endpoint MetSecondary TF Non-Inferiority Endpoint Met
8.0 %
Difference -4.2%
Upper 1-sided Upper 1-sided 95% CI95% CI2.3%2.3%
Difference -4.2%
Upper 1-sided Upper 1-sided 95% CI95% CI2.3%2.3%
Non-inferiority
P value
= 0.002
Non-inferiority
P value
= 0.002
-2.0-3.0
AVR (N = 244)
26.4%
AVR (N = 244)
26.4%
TAVR (N = 248)
22.2%
TAVR (N = 248)
22.2%
![Page 34: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/34.jpg)
104 83 72 28 8
103 72 68 30 9
29.0
27.9
TAVR
AVR
MonthsNo. at Risk
All-Cause MortalityAll-Cause MortalityTransapical (N=207)Transapical (N=207)
HR [95% CI] =1.22 [0.75, 1.98]
P (log rank) = 0.41
![Page 35: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/35.jpg)
Surgical AVR OutcomesSurgical AVR Outcomes
• Using an established predictive risk model (STS), the expected (“E”) 30-day mortality after AVR was 11.8%.
• The observed (“O”) 30-day mortality in the as-treated AVR control group was 8.0%.
• O:E = 0.68 indicates better than predicted surgical outcomes in the control AVR patients.
• There were no significant site or surgeon differences.
![Page 36: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/36.jpg)
All-Cause Mortality at 30 DaysAll-Cause Mortality at 30 DaysAll Patients
no. of patients ( %)TF Patients
no. of patients ( %)TA Patients
no. of patients ( %)
TAVR AVR p-value TAVR AVR p-value TAVR AVR p-value
ITT 12 (3.4) 22 (6.5) 0.07 8 (3.3) 15 (6.2) 0.13 4 (3.8) 7 (7.0) 0.32
AT 18 (5.2) 25 (8.0) 0.15 9 (3.7) 18 (8.2) 0.05 9 (8.7) 7 (7.6) 0.79
All-Cause Mortality at 1 YearAll-Cause Mortality at 1 YearAll Patients
no. of patients ( %)TF Patients
no. of patients ( %)TA Patients
no. of patients ( %)
TAVR AVR p-value TAVR AVR p-value TAVR AVR p-value
ITT 84 (24.2) 89 (26.8) 0.44 54 (22.2) 62 (26.4) 0.29 30 (29.0) 27 (27.9) 0.85
AT 81 (23.7) 78 (25.2) 0.64 51 (21.3) 55 (25.2) 0.33 30 (29.1) 23 (25.3) 0.55
All-Cause Mortality at 30 Days and 1 Year All-Cause Mortality at 30 Days and 1 Year ITT and ATT by SubgroupITT and ATT by Subgroup
![Page 37: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/37.jpg)
30 Days 1 Year
OutcomeOutcome TAVRTAVR(N = 348)(N = 348)
AVRAVR(N = 351)(N = 351) p-valuep-value TAVRTAVR
(N = 348)(N = 348)AVRAVR
(N = 351)(N = 351) p-valuep-value
All mortality – no. (%)All mortality – no. (%) 12 (3.4) 22 (6.5) 0.07 84 (24.2) 89 (26.8) 0.44
Cardiac mortality – no. (%) 11 (3.2) 10 (3.0) 0.90 47 (14.3) 40 (13.0) 0.63
Rehospitalization – no. (%) 15 (4.4) 12 (3.7) 0.64 58 (18.2) 45 (15.5) 0.38
Death or rehosp – no. (%)Death or rehosp – no. (%) 25 (7.2) 33 (9.7) 0.24 120 (34.6) 119 (35.9) 0.73
MI – no. (%) 0 2 (0.6) 0.16 1 (0.4) 2 (0.6) 0.69
Acute kidney inj* – no. (%) 10 (2.9) 10 (3.0) 0.95 18 (5.4) 20 (6.5) 0.56
Clinical Outcomes at 30 Days and 1 Year Clinical Outcomes at 30 Days and 1 Year All Patients (N=699)All Patients (N=699)
* Renal replacement therapy
![Page 38: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/38.jpg)
30 Days 1 Year
OutcomeOutcome TAVRTAVR(N = 348)(N = 348)
AVRAVR(N = 351)(N = 351) p-valuep-value TAVRTAVR
(N = 348)(N = 348)AVRAVR
(N = 351)(N = 351) p-valuep-value
Vascular complications
All – no. (%) 59 (17.0)59 (17.0) 13 (3.8)13 (3.8) <0.01<0.01 62 (18.0)62 (18.0) 16 (4.8)16 (4.8) <0.01<0.01
Major – no. (%)Major – no. (%) 38 (11.0)38 (11.0) 11 (3.2)11 (3.2) <0.01<0.01 39 (11.3)39 (11.3) 12 (3.5)12 (3.5) <0.01<0.01
Major bleeding – no. (%)Major bleeding – no. (%) 32 (9.3)32 (9.3) 67 (19.5)67 (19.5) <0.01<0.01 49 (14.7)49 (14.7) 85 (25.7)85 (25.7) <0.01<0.01
Endocarditis – no. (%) 0 (0.0)0 (0.0) 1 (0.3)1 (0.3) 0.320.32 2 (0.6)2 (0.6) 3 (1.0)3 (1.0) 0.630.63
New AF – no. (%)New AF – no. (%) 30 (8.6)30 (8.6) 56 (16.0)56 (16.0) < 0.01< 0.01 42 (12.1)42 (12.1) 60 (17.1)60 (17.1) 0.070.07
New PM – no. (%)New PM – no. (%) 13 (3.8)13 (3.8) 12 (3.6)12 (3.6) 0.890.89 19 (5.7)19 (5.7) 16 (5.0)16 (5.0) 0.680.68
Clinical Outcomes at 30 Days and 1 Year Clinical Outcomes at 30 Days and 1 Year All Patients (N=699)All Patients (N=699)
![Page 39: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/39.jpg)
30 Days 1 Year
OutcomeOutcome TAVRTAVR(N = 348)(N = 348)
AVRAVR(N = 351)(N = 351)
TAVRTAVR(N = 348)(N = 348)
AVRAVR(N = 351)(N = 351)
All Stroke or TIA – no. (%)All Stroke or TIA – no. (%) 19 (5.5)19 (5.5) 8 (2.4)8 (2.4) 0.040.04 27 (8.3)27 (8.3) 13 (4.3)13 (4.3) 0.040.04
TIA – no. (%) 3 (0.9) 1 (0.3) 0.33 7 (2.3) 4 (1.5) 0.47
All Stroke – no. (%) 16 (4.6) 8 (2.4) 0.12 20 (6.0) 10 (3.2) 0.08
Major Stroke – no. (%)Major Stroke – no. (%) 13 (3.8)13 (3.8) 7 (2.1)7 (2.1) 0.200.20 17 (5.1)17 (5.1) 8 (2.4)8 (2.4) 0.070.07
Minor Stroke – no. (%) 3 (0.9) 1 (0.3) 0.34 3 (0.9) 2 (0.7) 0.84
Death/maj stroke – no. (%)Death/maj stroke – no. (%) 24 (6.9)24 (6.9) 28 (8.2)28 (8.2) 0.520.52 92 (26.5)92 (26.5) 93 (28.0)93 (28.0) 0.680.68
Neurological Events at 30 Days and 1 Year Neurological Events at 30 Days and 1 Year All Patients (N=699)All Patients (N=699)
p-valuep-value p-valuep-value
![Page 40: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/40.jpg)
Months
348 289 252 143 65
351 247 232 138 63
No. at Risk
TAVR
AVR
28.0
26.5
HR [95% CI] =0.95 [0.73, 1.23]
P (log rank) = 0.70
All-Cause Mortality or StrokeAll-Cause Mortality or StrokeAll Patients (N=699)All Patients (N=699)
![Page 41: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/41.jpg)
NYHA Functional Class NYHA Functional Class
Baseline 1 Year6 Months30 Days
Pat
ient
s S
urvi
ving
, %
I II III IV
P = 1.00 P < 0.001 P = 0.05 P = 0.75
![Page 42: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/42.jpg)
Six-Minute Walk TestSix-Minute Walk TestAll Patients (N=699)All Patients (N=699)
Med
ian
Dis
tanc
e, m
eter
s
P = 0.73 P = 0.002 P = 0.33 P = 0.76
![Page 43: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/43.jpg)
SubgroupSubgroupTAVR (%)TAVR (%)
n=348n=348AVR (%) AVR (%)
n=351n=351RR RR
(95% CI) (95% CI) RR RR
(95% CI)(95% CI)P-value for P-value for
interactioninteraction
Overall 24.1 25.4 0.95(0.73-1.23)
Age<85>85
21.627.0
24.926.1
0.87(0.60-1.27)1.03(0.72-1.47)
0.52
SexMaleFemale
28.418.4
24.227.2
1.17(0.84-1.63)1.17(0.84-1.63)
0.045
BMI<26>26
27.321.0
27.423.8
0.68(0.44-1.04)0.99(0.71-1.40)
0.66
STS score<11>11
19.928.1
21.729.3
0.88(0.59-1.31)0.92(0.61-1.38)
0.87
LV ejection fraction
<55>55
26.222.4
27.722.1
0.96(0.69-1.34)1.01(0.68-1.50)
0.80
Subgroup Analyses of Treatment EffectSubgroup Analyses of Treatment Effect All-Cause Mortality at 1 YearAll-Cause Mortality at 1 Year
TAVR betterTAVR better AVR betterAVR better
0.5 1 2
![Page 44: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/44.jpg)
SubgroupSubgroupTAVR (%)TAVR (%)
n=348n=348AVR (%) AVR (%)
n=351n=351RR RR
(95% CI) (95% CI) RR RR
(95% CI)(95% CI)P-value for P-value for
interactioninteraction
Pulmonary hypertension
NoYes
21.327.4
21.729.9
0.98(0.64-1.50)0.92(0.66-1.28)
0.80
Mitral regurgitation
NoYes
24.624.2
22.135.2
1.11(0.82-1.52)0.69(0.41-1.17)
0.12
Prior CABGNoYes
22.225.9
30.719.1
0.72(0.52-1.01)1.35(0.88-2.08)
0.02
Peripheral vasc disease
NoYes
22.426.4
25.125.4
0.89(0.63-1.27)1.04(0.70-1.54)
0.57
Cohort TA TF
28.822.1
26.225.0
1.10(0.71-1.71)0.89(0.64-1.22)
0.43
TAVR betterTAVR better AVR betterAVR better
0.5 1 2
Subgroup Analyses of Treatment EffectSubgroup Analyses of Treatment Effect All-Cause Mortality at 1 YearAll-Cause Mortality at 1 Year
![Page 45: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/45.jpg)
Mean Gradient - AVR
Mean Gradient - TAVR
Peak Gradient - AVR
Peak Gradient - TAVR
Mea
n an
d P
eak
Gra
dien
tA
s-T
reat
ed T
rial A
rms
(mm
Hg)
50
40
30
20
60
70
10
0
80
Baseline 30 Days 6 Months 1 YearTAVR
n = 327AVR
n = 301TAVR
n = 287AVR
n = 231TAVR
n = 246AVR
n = 170TAVR
n = 227AVR
n = 159
Echo FindingsEcho FindingsAortic Valve GradientsAortic Valve Gradients
![Page 46: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/46.jpg)
Echo FindingsHemodynamic Assessments
30 Days 1 Year
Finding TAVR AVR TAVR AVR
AVG – mmHg 9.9 ± 4.8 10.8 ± 5.0 0.04 10.2 ± 4.3 11.5 ± 5.4 0.008
AVA - cm2 1.7 ± 0.5 1.5 ± 0.4 0.001 1.6 ± 0.5 1.4 ± 0.5 0.002
LVEF - % 55.5 ± 11.4 56.0 ± 11.4 0.63 56.6 ± 10.5 57.1 ± 10.3 0.64
p-value p-value
![Page 47: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/47.jpg)
Paravalvular Aortic RegurgitationParavalvular Aortic Regurgitation
P < 0.001 P < 0.001 P < 0.001
1 Year6 Months30 Days
Pat
ient
s, %
None Trace Mild Moderate Severe
![Page 48: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/48.jpg)
Study LimitationsStudy Limitations
• 8% of the control (AVR) group withdrew or refused assignedtherapy
• 5% of patients randomized to TAVR did not receiveassigned therapy (procedure aborted or converted to AVR)
• Significantly longer interval between randomization andtreatment in controls (AVR)
• An early version large TAVR delivery system was used
• Most sites had no previous TAVR experience - learningcurve impact inherent in TAVR, but not in AVR
• Insufficient statistical power to compare TA to either AVRor TF
• Long-term follow-up not available to assess TAVR durability
![Page 49: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/49.jpg)
Conclusions (1)Conclusions (1)
• The primary endpoint of the trial was met:– In patients with aortic stenosis at high risk for operation, TAVR
was non-inferior to AVR for all-cause mortality at 1 year (24.2% vs. 26.8%, p=0.001 for non inferiority)
– Transfemoral TAVR subgroup was also non-inferior toAVR (p=0.002 for non-inferiority)
• Death at 30 days was lower than expected in botharms of the trial:
– TAVR mortality (3.4%) was the lowest reported in any series, despite an early generation device and limited previous operator experience
– AVR mortality (6.5%) was lower than the expected operative mortality (11.8%)
![Page 50: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/50.jpg)
Conclusions (2)Conclusions (2)
• Both TAVR and AVR were associated with important but different peri-procedural hazards:
– Major strokes at 30 days (3.8 vs. 2.1%, p=0.20) and one year (5.1% vs. 2.4%, p=0.07) and major vascular complications were more frequent with TAVR (11.0% vs. 3.2%, p<0.001)
– Major bleeding (9.3% vs. 19.5%, p<0.001) and new onset atrial fibrillation (8.6% vs. 16.0%, p<0.001) were more frequent with AVR
• TAVR and AVR are both acceptable therapies in these high-risk patients; differing peri-procedural hazards should influence case-based decision-making
![Page 51: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/51.jpg)
Conclusions (3)Conclusions (3)
• Symptom improvement (NYHA class and 6-min walkdistance) favored TAVR at 30 days and was similar to AVR at one year
• Echo findings indicate:– Small hemodynamic benefit with TAVR vs. AVR at 1 year
(mean gradient p=0.008, AVA p=0.002)– Increased para-valvular regurgitation associated with
TAVR (p<0.001)
• Preliminary subgroup analyses should be interpretedcautiously:
– Possible TAVR benefit in women and patients without prior CABG
![Page 52: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/52.jpg)
ImplicationsImplications
• A multidisciplinary valve team approach benefits patients and is recommended for all future valve centers.
• TAVR is already the standard-of-care for inoperable patients with severe aortic stenosis. These results indicate that TAVR is an acceptable alternative to AVR in selected high-risk operable patients.
• Future randomized studies should focus on lower risk patients who are candidates for operation.
![Page 53: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/53.jpg)
Back-up SlidesBack-up Slides
![Page 54: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/54.jpg)
PARTNER Comparison of OutcomesPARTNER Comparison of OutcomesHigh-Risk vs. Inoperable PatientsHigh-Risk vs. Inoperable Patients
Per
Cen
t (%
)
5.0
11.0
![Page 55: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/55.jpg)
TAVR AVR
ComplicationComplication WithWith WithoutWithout WithWith WithoutWithout
Stroke or TIA
All Patients – no. 31 313 16 297
Died Died ≤ 30 days – no. (≤ 30 days – no. (%)%) 2 (6.5)2 (6.5) 16 (5.1)16 (5.1) 1 (6.3)1 (6.3) 24 (8.1)24 (8.1)
Died ≤ 1 year – no. (%)≤ 1 year – no. (%) 10 (32.3) 71 (22.8) 3 (18.8) 75 (25.6)
Major Stroke
All Patients – no. 18 326 11 302
Died Died ≤ 30 days – no. (≤ 30 days – no. (%)%) 2 (11.1) 16 (4.9) 1 (9.1) 24 (8.0)
Died ≤ 1 year – no. (%)≤ 1 year – no. (%) 9 (50.0) 72 (22.2) 3 (27.3) 75 (25.1)
Neurological Events and Mortality Neurological Events and Mortality at 30 Days and 1 Year (as treated)at 30 Days and 1 Year (as treated)
![Page 56: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/56.jpg)
TAVR AVR
ComplicationComplication WithWith WithoutWithout WithWith WithoutWithout
Major Vascular
All Patients – no. 38 306 11 302
Died Died ≤ 30 days – no. (≤ 30 days – no. (%)%) 6 (15.8)6 (15.8) 12 (3.9)12 (3.9) 2 (19.2)2 (19.2) 23 (7.6)23 (7.6)
Died ≤ 1 year – no. (%)≤ 1 year – no. (%) 14 (37.3) 67 (22.0) 5 (49.5) 73 (24.4)
Major Bleeding
All Patients – no. 52 292 88 225
Died Died ≤ 30 days – no. (≤ 30 days – no. (%)%) 2 (3.8) 16 (5.5) 15 (17.1) 10 (4.5)
Died ≤ 1 year – no. (%)≤ 1 year – no. (%) 16 (31.1) 65 (22.3) 36 (41.3) 42 (18.9)
Vascular/Bleeding Events and Mortality Vascular/Bleeding Events and Mortality at 30 Days and 1 Year (as treated)at 30 Days and 1 Year (as treated)
![Page 57: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/57.jpg)
All-Cause Mortality (As Treated TAVR Trial Arm)All-Cause Mortality (As Treated TAVR Trial Arm)Stratified by Major StrokeStratified by Major Stroke
Months
![Page 58: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/58.jpg)
All-Cause Mortality (As Treated TAVR Trial Arm)All-Cause Mortality (As Treated TAVR Trial Arm)Stratified by Major Vascular EventStratified by Major Vascular Event
Months
![Page 59: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/59.jpg)
All-Cause Mortality (As Treated TAVR Trial Arm)All-Cause Mortality (As Treated TAVR Trial Arm)Stratified by Major BleedStratified by Major Bleed
Months
![Page 60: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/60.jpg)
All-Cause Mortality (As Treated AVR Trial Arm)All-Cause Mortality (As Treated AVR Trial Arm)Stratified by Major StrokeStratified by Major Stroke
Months
![Page 61: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/61.jpg)
All-Cause Mortality (As Treated AVR Trial Arm)All-Cause Mortality (As Treated AVR Trial Arm)Stratified by Major BleedStratified by Major Bleed
Months
![Page 62: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/62.jpg)
All-Cause Mortality (As Treated AVR Trial Arm)All-Cause Mortality (As Treated AVR Trial Arm)Stratified by New Atrial fibrillationStratified by New Atrial fibrillation
Months
![Page 63: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/63.jpg)
All-Cause Mortality All-Cause Mortality (As Treated)(As Treated)Pooled Implant Approaches (N= 657)Pooled Implant Approaches (N= 657)
Months
344 291 258 139 64
313 243 226 128 60
No. at Risk
TAVR
AVR
25.2
23.7
HR [95% CI] =1.02 [0.77, 1.36]
P (log rank) = 0.88
![Page 64: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/64.jpg)
Primary Endpoint: (As Treated)Primary Endpoint: (As Treated)All-Cause Mortality at 1 YearAll-Cause Mortality at 1 Year
7.0-2.0 -1.0 0.0 6.03.0 4.0 5.0-3.0
Zone of non-inferiority pre-specified margin = 7.5%
1.0 2.0
Non-inferior
Upper one-sided 95% CI
Primary Non-Inferiority Endpoint MetPrimary Non-Inferiority Endpoint Met
8.0 %
Difference -1.6%
Upper 1-sided Upper 1-sided 95% CI95% CI4.0%4.0%
Difference -1.6%
Upper 1-sided Upper 1-sided 95% CI95% CI4.0%4.0%
Non-inferiority
P value
= 0.004
Non-inferiority
P value
= 0.004
AVR (N = 313)
25.2%
AVR (N = 313)
25.2%
TAVR (N = 344)
23.6%
TAVR (N = 344)
23.6%
![Page 65: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/65.jpg)
All-Cause Mortality All-Cause Mortality (As Treated)(As Treated)Transfemoral (N=461)Transfemoral (N=461)
Months
240 209 186 112 58
221 172 161 100 53
No. at Risk
TAVR
AVR
25.2
21.3
HR [95% CI] =0.90 [0.64, 1.26]
P (log rank) = 0.53
![Page 66: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/66.jpg)
Powered Secondary Endpoint (AT):Powered Secondary Endpoint (AT):TF All-Cause Mortality at 1 YearTF All-Cause Mortality at 1 Year
7.0-4.0 -1.0 0.0 6.03.0 4.0 5.0-5.0
Zone of non-inferiority pre-specified margin = 7.5%
1.0 2.0
Non-inferior
Upper one-sided 95% CI
Secondary TF Non-Inferiority Endpoint MetSecondary TF Non-Inferiority Endpoint Met
8.0 %
Difference -3.9%
Upper 1-sided Upper 1-sided 95% CI95% CI2.6%2.6%
Difference -3.9%
Upper 1-sided Upper 1-sided 95% CI95% CI2.6%2.6%
Non-inferiority
P value
= 0.002
Non-inferiority
P value
= 0.002
-2.0-3.0
AVR (N = 221)
25.2%
AVR (N = 221)
25.2%
TAVR (N =240 )
21.3%
TAVR (N =240 )
21.3%
![Page 67: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/67.jpg)
All-Cause Mortality All-Cause Mortality (As Treated)(As Treated)Transapical (N=196)Transapical (N=196)
Months
104 82 72 27 6
92 71 65 28 7
No. at Risk
TAVR
AVR
25.3
29.1
HR [95% CI] =1.36 [0.82, 2.26]
P (log rank) = 0.23
![Page 68: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/68.jpg)
All-Cause Mortality All-Cause Mortality Stratified by ITT Trial Arm and Patient GenderStratified by ITT Trial Arm and Patient Gender
![Page 69: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/69.jpg)
All-Cause Mortality All-Cause Mortality Stratified by ITT Trial Arm and Prior CABGStratified by ITT Trial Arm and Prior CABG
![Page 70: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/70.jpg)
All-Cause Mortality All-Cause Mortality Stratified by ITT Trial Arm and Prior CABGStratified by ITT Trial Arm and Prior CABG
![Page 71: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/71.jpg)
All-Cause Mortality All-Cause Mortality Stratified by ITT trial arm and Moderate/Severe MRStratified by ITT trial arm and Moderate/Severe MR
![Page 72: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/72.jpg)
Echo FindingsEcho FindingsValvular RegurgitationValvular Regurgitation
30 Days 1 Year
Finding – no. (%)Finding – no. (%) TAVRTAVR AVRAVR TAVRTAVR AVRAVR
Transvalv. Regurg.
Mod/Severe3 (1.0) 2 (0.9) <.0001 2 (0.9) 0 (0.0) <.0001
Paravalv. Regurg.Paravalv. Regurg.
Mod/SevereMod/Severe35 (12.2)35 (12.2) 2 (0.9)2 (0.9) <.0001<.0001 15 (6.8)15 (6.8) 3 (1.9)3 (1.9) <.0001<.0001
All Regurg.
Mod/Severe21 (7.7) 4 (1.7) <0.001 12 (5.5) 3 (1.9) <0.001
p-valuep-value p-valuep-value
![Page 73: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/73.jpg)
Echo FindingsEcho FindingsParavalvular RegurgitationParavalvular Regurgitation
30 Days 1 Year
Finding – no. (%)Finding – no. (%) TAVRTAVR AVRAVR TAVRTAVR AVRAVR
None 65 (22.6) 168 (73.7) <.0001 73 (32.9) 123 (77.8) <.0001
Trace/Mild Trace/Mild 187 (65.2)187 (65.2) 58 (25.4)58 (25.4) <.0001<.0001 134 (60.4)134 (60.4) 32 (20.3)32 (20.3) <.0001<.0001
Mod/Severe 35 (12.2)35 (12.2) 2 (0.9)2 (0.9) <.0001<.0001 15 (6.8)15 (6.8) 3 (1.9)3 (1.9) <.0001<.0001
p-valuep-value p-valuep-value
![Page 74: Craig R. Smith, MD on behalf of The PARTNER Trial Investigators](https://reader033.fdocuments.us/reader033/viewer/2022052701/56812a78550346895d8e01f4/html5/thumbnails/74.jpg)
AVR
TAVR
Val
ve A
rea,
cm
2
Aortic Valve AreaAortic Valve AreaAs Treated Trial ArmsAs Treated Trial Arms
TAVRn = 319
AVRn = 297
TAVRn = 279
AVRn = 228
TAVRn = 235
AVRn = 165
TAVRn = 219
AVRn = 155